Viewing nowCombinationNexglipin Duo Tablet 50/850 mg
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Bionex Co., Ltd.

MFDS item code 202200119 · Approved 2022.01.06 · Insurance code 643105770
Improvement of blood glucose control in type 2 diabetes mellitus
This drug helps patients with type 2 diabetes effectively control their blood sugar along with diet and exercise therapy. It is used when they have never received other diabetes medications before or when it is difficult to control blood sugar with monotherapy alone. It can also be used when sufficient effect is not achieved with monotherapy of Metformin or Sitagliptin, or to replace combination therapy of these two medications. If blood sugar control is insufficient even with combination therapy of Metformin and sulfonylureas, Metformin and thiazolidinediones, and insulin and Metformin, the addition of this drug can be applied. In summary, this drug is used to improve blood sugar control in type 2 diabetes.
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see section 2. Patients who must not take this medicine under Precautions for Use). 2. Patients receiving metformin: - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should take the patient's blood glucose level and current dose into account. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia caused by the sulfonylurea or insulin (see section 5. General Precautions under Precautions for Use). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with other oral antihyperglycemic agents. Any change in treatment for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used, with the following dose adjustment, in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate [eGFR] ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see section 2. Patients who must not take this medicine under Precautions for Use).
This drug contains Sitagliptin and Metformin and is used for the treatment of type 2 diabetes. When taking this drug, serious allergic reactions may occur, so if symptoms such as skin rash, hives, or difficulty breathing appear, discontinue use immediately and consult a physician. Acute pancreatitis may occur, so inform medical staff immediately if symptoms like abdominal pain, nausea, or vomiting appear. Patients with severe renal impairment or those in acute conditions, dehydration, or severe infection should not take this drug. Additionally, patients with acute cardiovascular issues like acute heart failure, acute myocardial infarction, or sepsis may be at risk if they use this drug. Before and after examinations using iodinated contrast agents, administration of this drug should be temporarily suspended and can only be resumed after kidney function is confirmed to be normal. Pregnant women, women who may become pregnant, and breastfeeding women should not take this drug. While taking this drug, care must be taken as irregular meals, excessive exercise, and drug interactions can lead to hypoglycemia or lactic acidosis. Symptoms of hypoglycemia include dizziness, trembling, and cold sweat, and if these symptoms occur, sugar should be consumed immediately. This drug may affect liver and kidney function, so regular blood tests and kidney function tests should be performed before and during treatment. Especially in the elderly, kidney function may decline, so careful monitoring is essential. Alcohol consumption can increase the risk of lactic acidosis when taken with this drug, so avoid excessive drinking. If oral intake is difficult due to surgery or severe illness, temporarily discontinue this drug and resume after recovery. If blisters or severe joint pain occur while taking this drug, inform a doctor immediately and discontinue use if necessary. In case of overdose, visit a medical institution immediately for proper treatment, as this drug can be partially removed through hemodialysis. While taking this drug, regular meals, exercise, and periodic blood sugar and kidney function tests are very important.
Anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, lactic acidosis, hypoglycemia, diarrhea, upper respiratory tract infection, headache, nausea, vomiting, abdominal pain, nasopharyngitis, constipation, arthralgia with severe and disability-associated symptoms, bullous pemphigoid, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, elevated liver enzymes, acute renal failure, dyspnea, unstable angina, dizziness, reduced appetite, itching, dermatitis, weight loss, hypoglycemic adverse reactions, severe arthralgia, bullous pemphigoid, anemia, decreased serum vitamin B12
Not everyone experiences these, and they can vary from person to person.
This drug should be stored in a tightly sealed container to prevent air from entering and should be kept at a temperature between 1 and 30 degrees Celsius. This storage method helps maintain the drug's effectiveness and prevents deterioration.
Pink oval film-coated tablet
30 tablets/box [(10 tablets/PTP x 3)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Bionex Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Eden Pharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.